The rising incidence of multidrug-resistant Gram-negative bacterial (MDR-GNB) infections acquired in intensive care units has prompted a variety of patient-level infection control efforts. However, it is not known whether these measures are effective in reducing colonisation and infection. The purpose of this systematic review was to assess the efficacy of patientlevel interventions for the prevention of colonisation with MDR-GNB and whether these interventions are associated with a reduction in the rate of infection due to MDR-GNB in the intensive care unit. Searches were conducted on PubMed, Cochrane, EMBASE and World of Science databases to identify comparative interventional studies on patient-level interventions implemented in the intensive care unit. Literature published in English, Spanish or French from January 1, 2000, until April 30, 2013, was searched. A total of 631 reports were found and we included and analysed 13 comparative studies that reported outcomes for an intervention compared with a control group. There were ten randomised and three observational interventional trials evaluating seven interventions. Overall, there was a reduction in colonisation (odds ratio [OR] 0.75; 95% confidence interval [CI] 0.66 to 0.85) and infection (OR 0.66; 95% CI 0.59 to 0.75) with MDR-GNB. This trend persisted after restricting pooled analysis to randomised controlled trials (pooled OR 0.66; 95% CI 0.57 to 0.76 and pooled OR 0.62; 95% CI 0.54 to 0.72, respectively). We identified a significant reduction in MDR-GNB colonisation and infection through the use of patient-level interventions. This effect was mostly accounted for by selective digestive decontamination. However, given the limitations of the analysed trials, adequately powered controlled studies are needed to further explore the effects of patientlevel interventions on colonisation and infection with MDR-GNB.
The number of multidrug-resistant Gram-negative bacteria (MDR-GNB) is continuously rising. Between 1986 and 2003, the proportion of Enterobacteriaceae resistant to third generation cephalosporins has increased by more than tenfold; resistant Klebsiella pneumoniae, Pseudomonas aeruginosa 1 , Acinetobacter species 2 and Escherichia coli have increased twofold 2 . Despite this increased prevalence, novel therapeutics to treat MDR-GNB infections promoted through industry pipelines are few 3 . Infection with MDR-GNB is associated with increased mortality 4 , length-of-hospital-stay and hospital costs 5 . In an attempt to prevent the transmission of drug resistant bacteria, professional organisations have published guidelines 6 suggesting hospital-and intensive care unit (ICU)-based standard infection control strategies. However, little evidence is available on the effectiveness of these measures regarding the prevention of infection with MDR-GNB. There are several explanations for the challenges of these investigations, including the following: 1) the continually changing pattern of antimicrobial resistance 7 , 2) the lack of sensitive and rapid laboratory tests to detect antimicrobial resistance 8 and 3) the ongoing debate regarding which patient population requires the initiation of routine surveillance cultures and preventative infection control measures 9 . As a result of these challenges, multiple investigators have introduced infection control measures that target the patient. These patient-level interventions target specific areas of the body thought to be reservoirs for bacterial colonisation and possible downstream infections. Despite the appeal of these interventions, the efficacy of these measures on the incidence of colonisation and infection with MDR-GNB is unclear.
This systematic review has two objectives. First, to evaluate the range of patient-level interventions, beyond universal precautions, that have been evaluated for their effectiveness in reducing colonisation, and second, to explore whether these interventions, targeted at reducing colonisation, reduce infections with MDR-GNB. The overall goal is to prioritise which patient-level interventions should be evaluated more extensively and implemented more broadly. We hypothesised that patient-level interventions are not effective in preventing colonisation and that reduction of colonisation is not associated with a decreased risk of infection.
Materials and methods

Search Strategy
We searched the PubMed, EMBASE, World of Science and Cochrane databases covering the time period from January 1, 2000, to April 14, 2013 , using the following key words: "Gram-negative bacteria", AND "intensive care unit", AND "adult", AND "drug resistant"; combined with each of the following: "colonisation", OR "surveillance cultures", OR "hospital-acquired infection", OR "ventilator-associated pneumonia [VAP]", OR "urinary tract infection", OR "catheter-related blood stream infection". Searches included literature written in English, Spanish, Italian or French.
Study selection
We included studies that collected original data on adults in the ICU. We excluded animal studies and studies whose subjects were less than 18 years of age, pregnant or immunocompromised.
Study design
We included studies that reported details about MDR-GNB, including information about the site of colonisation, method of infection diagnosis, name, number and detection method of resistance to antibiotics and the species of bacteria isolated from colonisation or infection sites. We restricted eligibility to studies reporting interventions to prevent colonisation or infection and those with appropriate comparison groups. Case reports, case series, abstracts from scientific meetings and reviews were excluded.
Data extraction
Two authors screened the titles and abstracts of all reports. All abstracts that did not explicitly meet our predefined inclusion criteria were excluded. Full text articles were then retrieved and the same authors scrutinised the retrieved reports to ensure that all inclusion criteria were met. Discrepancies in the interpretation of the reports were resolved by discussion among all authors to reach a consensus. Key information from each study was abstracted using a priori defined criteria in a systematic approach. We considered both combined counts of subjects reported as colonised or infected with MDR-GNB and subjects colonised or infected with other drug-resistant bacteria. We used each study's original definition of antibiotic resistance, colonisation or infection. The term 'acquisition' was considered synonymous with 'colonisation'. The number of patients included in the analysis was recorded. If the study reported the number of patients analysed but did not report the number of patients originally enrolled, we assumed that the study used an intentto-treat approach and considered the reported number of patients included in the analysis to correspond to the number of patients originally enrolled.
Data collection
Patient information across the studies included the following data: average age of study participants, gender distribution, disease severity score, type of ICU population, colonisation or infection site, type of pathogen, number and types of antibiotics and use of vasoactive drugs.
Definition of endpoints for the meta-analysis
The primary endpoint regarding colonisation was the new acquisition of MDR-GNB. Colonisation was defined as the isolation of MDR-GNB from the respiratory, gastrointestinal or urinary tracts; nose, rectum and intravascular or urinary catheters in the absence of signs of infection. The secondary endpoint was progression to infection with MDR-GNB. This endpoint was defined as any nosocomial infection for which the causative pathogens were MDR-GNB. When the original authors classified infections as 'possible', 'probable' or 'definitive', only the latter two were considered to indicate infectious events. In the reports, we also searched for the following secondary endpoints: length-of-ICU-stay, duration of mechanical ventilation and hospital mortality.
Internal validity of randomised trials
For randomised studies, we used the Jadad scale 10 to score the quality of the studies included in this analysis.
Pooled data analysis
We explored the pooled effects of interventions to evaluate the size of the effect on infection with MDR-GNB. The intent of this analysis was to account for the small sample of many studies that were possibly underpowered, to evaluate whether an intervention led to reduction in colonisation or infection. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using both the Mentel-Haenszel11 fixed effects approach and the DerSimonian-Laird random effects model12. Three pooled analyses were conducted with the following endpoints: 1) colonisation with MDR-GNB, 2) infection caused by MDR-GNB and 3) hospital and ICU mortality. The heterogeneity in effect across studies was assessed using the chi-square statistic, where a P-value <0.10 was used to denote statistical significance in the analysis of heterogeneity. The reported ORs of the analysed studies were weighted by the inverse of their variance. Pooled analyses were performed using STATA version 12.1 (STATACorp, College Station, TX, USA).
Results
Search results
The initial literature search identified 631 potential articles, of which 469 studies were excluded because they either did not contain appropriate control groups, lacked pertinent information or were conducted in a non-ICU setting. Full text articles were retrieved for 162 studies. Of these, 153 (94.4%) did not meet inclusion criteria. One study 13 appeared to meet the inclusion criteria. However, the results were reported as colonisation and infection rates without details regarding the number of patients colonised or infected and additional data could not be obtained from the original authors. A flow diagram detailing the reasons for exclusion is shown in Figure 1 . The studies meeting our inclusion criteria included ten randomised controlled trials [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] and three comparative observational studies [24] [25] [26] . Of note, the study by Oudhuis et al 17 was terminated early after the publication of an association between the use of probiotics and increased mortality in patients with acute pancreatitis 27 . In assessing the quality of these studies, the studies by de Smet et al 21, 22 , Forestier et al 15 and Fourier et al 18 met all five Jadad criteria 10 . The study by Saidel-Odes et al 23 was assigned a score of three for lacking a description of dropouts. The studies by Heyland et al 16 , Topeli et al 19 and de Jonge et al 14 were assigned Jadad scores of three for lack of blinding. The study by Oudhuis et al 17 was assigned a score of two for lack of blinding and early termination.
Patient-level interventions
These studies examined seven different types of patient-level interventions designed to prevent infection with MDR-GNB, all of which were implemented in addition to standard hospital-based infection control practices (Table 1 ). These interventions included closed endotracheal tube (ETT) suction for mechanically ventilated patients, empiric double antibiotic coverage for suspected late VAP, selective digestive decontamination, administration of probiotics, gingival and dental antiseptic decontamination and antibiotic cycling to prevent infection with MDR-GNB. Except for the studies by Topeli et al 19 28 only reported infection as the study endpoint. The other studies reported both colonisation and infections, including VAP, urinary tract infection, catheter-related infection and bloodstream infections. Antibiotics, for which resistance was identified, varied among studies and included two or more of the antibiotic classes-β-lactams, cephalosporins, carbapenems and fluoroquinolones. 
Characteristics of patients across studies
The characteristics of the study population included in the studies are described in Table 2 . Sample sizes varied from a total of 78 subjects 19 to 1172 patients 24 . The study by Francetic et al 28 did not report patient baseline characteristics. Ethnic background was only reported by Warren et al 24 . The mean age ranged from 59 to 64 years. All studies enrolled more males than females. As expected of studies conducted in the ICU, all studies included populations with high severity scores. Studies inconsistently reported hospital days prior to enrolment and total ICU and hospital days. For example, Topeli et al 19 
Primary endpoint of colonisation with MDR-GNB
Eleven of 13 studies reported the effect of patient-level interventions on the incidence of colonisation, with four studies 14, 15, 21, 23 observing reductions in the incidence of colonisation and six studies [16] [17] [18] [19] 24, 25 finding no difference in the incidence of colonisation between the study groups ( 16 found that sputum colonisation by MDR-GNB did not significantly differ between the intervention group and the control group. However, they observed microbiological eradication in a subgroup of 56 patients colonised at baseline in the combination therapy group compared with the monotherapy group. In a comparative observational study of antibiotic cycling, Warren et al 24 did not observe a significant difference in the enteric acquisition of Pseudomonas species (relative risk 0.96; 95% CI 0.47, 2.16) and Enterobacteriaceae (relative risk 1.57; 95% CI 0.80, 3.43). Examining the effects of dental plaque antiseptic decontamination, Fourrier et al 18 found a significant reduction (P <0.05) between the study groups only in the subgroup of patients who were colonised at enrolment and who remained positively colonised at ten days after enrolment. Examining the effects of antibiotic cycling versus antibiotic mixing on the acquisition of MDR-GNB, Martinez et al 25 did not observe a significant difference between the study groups. The colonisation endpoint from the pooled analysis is shown in Figure 2 . The pooled effect size for all interventions combined showed a significant reduction of colonisation (pooled OR 0.75; 95% CI 0.66 to 0.85).
When we restricted our analysis to randomised control trials only [14] [15] [16] [17] 19 , the estimates showed a statistically significant effect of all interventions on the reduction of MDR-GNB colonisation (pooled OR 0.66; 95% CI 0.57 to 0.76). The pooled analysis of randomised control trials showed significant heterogeneity (chi-squared test=19.3; df=8; P=0.01).
Secondary endpoints
Infection with MDR-GNB
Six studies [15] [16] [17] 19, 21, 28 reported the results of patientlevel interventions on the incidence of infection (Figure 1 15 reported a trend towards a negative association, suggesting that the intervention potentially decreased the incidence of infection. de Smet et al's study found a significant reduction in the incidence of bacteraemia in the intervention groups (SDD: OR 0.48; 95% CI 0.38 to 0.60, and SOD: OR 0.66; 95% CI 0.53 to 0.82) 21 . In contrast, three other studies 17, 19, 24 showed positive associations, suggesting that the interventions potentially increased the incidence of infection, although the results were not significant for any individual study.
The pooled effect size of all interventions showed a significant reduction in the odds of infection with MDR-GNB (pooled OR 0.66; 95% CI 0.59 to 0.75) (Figure 3 ). This estimate remained substantially unchanged after restricting the analysis to randomised control trials only (pooled OR 0.62; 95% CI 0.54 to 0.72). The pooled analysis of randomised control trials showed significant heterogeneity (P <0.01).
Mortality
Eight studies 14, 16, [18] [19] [20] 22, 24, 25 reported the effect of their interventions on mortality outcomes including ICU, hospital and overall 28-day mortality. Among all interventions, only SDD was associated with a reduction of ICU mortality from MDR-GNB. The overall effect of the seven interventions combined did not show a significant effect on mortality (pooled OR 1.03; 95% CI 0.95 to 1.1). The pooled analysis showed heterogeneity among studies (P=0.05, Figure 4 ).
Other clinical endpoints
The lengths of both ICU and hospital stays were reported by some studies 15, 17, 20 and one study only reported the mean length of ICU stay 24 . Among the studies reporting the effect of patient-level interventions on ICU length-of-stay, Warren et al 24 showed a longer ICU stay in the intervention group compared with the baseline group (8.7 versus 7.7, P=0.01). In contrast, Melsen et al 20 reported a significantly shorter length-of-ICU-stay (adjusted hazard ratio 1.15; 95% CI 1.03 to 1.28; P=0.01) and hospital stay (adjusted hazard ratio 1.17; 95% CI 1.01 to 1.35; P=0.032) in the surgical patients in the SDD group compared with the standard of care group. Interestingly, only the non-surgical patients in the SOD group in the same study showed a significantly shorter hospitallength-of-stay (adjusted hazard ratio 1.18; 95% CI 1.02 to 1.37; P=0.027) compared with the standard of care group. Four studies 16, 18, 19, 25 reported no significant differences between the intervention and control groups in the duration of mechanical ventilation.
Discussion
In this systematic review, we found that a variety of patientlevel interventions were associated with a reduction in colonisation and infection with MDR-GNB in an ICU setting. Reduction in colonisation with MDR-GNB translated into a reduction in infection. These associations were mostly contributed by SDD. Studies on SDD carried more weight because of their higher quality and larger sample size. Of all patientlevel interventions reviewed, only SDD was associated with a reduction in MDR-GNB induced ICU mortality.
To our knowledge, this is the first analysis reporting the pooled effects of patient-level interventions on colonisation and infection with MDR-GNB. Only 13 adequately designed studies were eligible for this systematic review. Exclusions were due to the methodological limitations of most studies that were primarily designed without a comparison group or failed to report important infection and colonisation endpoints. The largest randomised controlled trial was excluded from our analysis because the results were reported in terms of outcomes per catheter rather than number of patients, precluding its inclusion in our pooled analysis. In this study, Timsit et al 13 demonstrated the non-inferiority of chlorhexidine-gluconate-impregnated catheter dressings (versus povidone-iodine-based dressings) and less frequent (every seven days versus every three days) central venous catheter dressing changes on the incidence of colonisation and catheter related infections. Similarly, a multicentre randomised controlled study performed by Arvaniti et al 29 was excluded from the analysis because outcomes were reported in terms of the number of catheters rather than number of patients. In this study, there was no significant difference between silver-impregnated (Oligon) central venous catheters and chlorhexidine gluconate-impregnated sponge-covered standard central venous catheters compared with standard central venous catheters with regard to the incidence of catheter colonisation and infection with MDR-GNB.
While the use of probiotics and SDD were shown to decrease the acquisition of MDR-GNB compared to standard therapy 14, 15 , these interventions failed to demonstrate significant superiority when compared to each other 17 . The lack of a pronounced effect may be due to comparable beneficial effects of both interventions, or it may be due to early discontinuation of the trial by Oudhuis et al 17 .
Our finding of an association between patient-level interventions in the ICU and colonisation is in agreement with a recent meta-analysis by Siempos et al 26 that concluded that probiotics were associated with a reduction in the incidence of colonisation of the respiratory tract by Pseudomonas aeruginosa, as well as a reduction in the incidence of VAP and shorter hospital length-of-stay 30 . Compared to our review, Siempos et al included five studies, focused on both Gramnegative and Gram-positive bacteria, included studies that did not address antibiotic resistance and only focused on one patient-level intervention. Similar to our systematic review, Siempos et al did not observe a difference in mortality associated with probiotics administered in the ICU. A similar reduction in the incidence of VAP was found in a recent qualitative review 31 on the use of probiotics and SDD as prophylactic measures against VAP, which was not restricted to MDR-GNB. In their review of 79 studies, the authors reported a trend towards a reduction in the incidence of VAP with the use of probiotics. However, safety concerns were raised by a multicentre randomised placebo-controlled trial that found an increase in mortality in patients with severe acute pancreatitis who were given probiotics species 32 . Due to these conflicting results and the safety concerns, the role of probiotics as a prophylactic intervention against MDR-GNB bacterial colonisation remains debatable and it is likely that probiotics should be considered more harmful than beneficial due to the lack of effect on infection observed in the present systematic review. More studies are needed to investigate the immunemodulatory role of different preparations of probiotics and the effects of probiotics on bacterial colonisation, infection and ultimate patient outcomes.
Multiple meta-analyses and systematic reviews have investigated the role of SDD and SOD in the prevention of colonisation and infections in ICU populations. In a Cochrane review 33 of 36 randomised controlled trials (6914 patients), the use of prophylactic topical and systemic SDD was associated with a reduction in the incidence of VAP and bloodstream infections caused by GNB. Similar findings were reported by Silvestri et al 34 in a meta-analysis of 51 randomised controlled trials (8065 patients) that evaluated the effect of oropharyngeal and intestinal administration of antibiotics as part of the SDD protocol, with or without systemic antibiotics, on the incidence of bloodstream infections and mortality. Both reviews showed a significant reduction in mortality by SDD. However, neither review specifically addressed MDR-GNB. Consistent with our findings, a recent meta-analysis 35 of 64 studies on SDD and SOD found no increase in the incidence of GNB nor of Gram-positive bacterial resistance in the ICU 35 , a potentially reassuring finding of the safety of SDD/SOD. A recent large, multicentre, randomised controlled study 36 demonstrated that universal decolonisation of ICU patients using nasal mupirocin ointment and daily baths using a chlorhexidineimpregnated cloth was associated with a lower incidence of methicillin-resistant Staphylococcus aureus colonisation and bloodstream infection. However, there were no data on resistant GNB in this study. Therefore, sufficiently powered studies that specifically target MDR-GNB under standardised decolonisation methods are needed to investigate the longterm effects of this strategy on ICU-level microbial resistance.
Our study did not show a significant difference in the colonisation with MDR-GNB between empiric combination therapy of meropenem and ciprofloxacin versus meropenem monotherapy for late suspected VAP. On the contrary, there was a trend towards an increase in mortality and colonisation with antibiotic cycling. A meta-analysis 37 conducted by Paul et al found no significant difference in treatment failure, clinical failure, rate of emergence of resistant bacteria and all-cause mortality between β-lactam-aminoglycoside combination therapy compared with β-lactam monotherapy for severe Gram-negative sepsis. The same study demonstrated a significantly higher incidence of nephrotoxicity in combination therapy compared with monotherapy. Similar findings were reported in a Cochrane meta-analysis 38 . Taken together, there is no current proven benefit of empiric combination antibiotic coverage for suspected late VAP.
Our review has several limitations. First, the studies included in our analyses were generally underpowered, and had inconsistency in reporting outcomes, implementing standard infection control measures and follow-up of the target population. Moreover, the reporting on the timing of acquisition of MDR-GNB was inconsistent. Because of the limited number of studies, we combined different interventions to explore their general effect on patient outcomes. Pooling these diverse studies may not detect important effects if some types of interventions are beneficial while others are less so. Secondly, data were often reported inconsistently and we had to make several key assumptions, such as the appropriateness of each study's methods for defining antimicrobial resistance, documenting infections and general follow-up assessment. It is possible that differences across studies in these methods may introduce potential biases. Thirdly, it should be emphasised that the implementation of infection-control measures that influence patient outcomes occurs along a continuum. For example, a lack of implementation of effective hospital infection-control measures prior to ICU admission is likely to be associated with worse patient outcomes, even if these measures were adequately implemented after ICU admission. Therefore, the lack of efficacy of a patientlevel intervention might be due to lack of implementation of adequate infection-control measures prior to ICU admission rather the intervention itself. None of the studies listed in this review emphasised the adequacy of infection-control measures prior to ICU admission. Additionally, the lack of a reduction in infection as a result of a reduction of colonisation with MDR-GNB in some studies may be explained by the lack of data on infection rates in these studies 14, 16 , which might have led to an underestimation of the relationship between colonisation and infection. Fourthly, it should be emphasised that SDD, although shown in our review to be an effective patientlevel intervention, has not been subjected to long-term follow-up studies to investigate the emergence of MDR-GNB.
Our systematic review includes both randomised controlled trials and comparative cohort studies. According to our a priori plan for the preparation of this systematic review, we had planned to include randomised trials, but we also planned to potentially include cohort studies because we had anticipated a possible paucity of high quality randomised trials. The authors believe that including randomised controlled trials and observational studies might have enhanced our ability to detect an effect given the larger sample size. Drawbacks of this approach are the possible increase in heterogeneity among studies and the introduction of possible confounding bias (from observational studies). The former would bias our estimates toward the null, while the latter might bias them away from the null. Because our results on the prevention of colonisation and reduction of infection were the same with and without restriction to randomised trials only, we do not believe that confounding bias operates to a great extent in these data.
Conclusion
Patient-level interventions seem to be associated with a reduction in colonisation and infection by MDR-GNB. Moreover, reduction of colonisation seems to prevent downstream infection. SDD is the single intervention associated with a reduction in both colonisation and infection and ICU mortality. Probiotics are associated with a reduction in colonisation with MDR-GNB. Antibiotic cycling with amikacin is associated with a reduction in MDR-GNB infection. Sufficiently powered studies are needed to investigate the role of individual patient-level interventions on infection and clinically meaningful endpoints and to explore other means of reducing acquisition or infection with MDR-GNB in the ICU.
